188 related articles for article (PubMed ID: 36892415)
1. Genetically identical twin-pair difference models support the amyloid cascade hypothesis.
Coomans EM; Tomassen J; Ossenkoppele R; Tijms BM; Lorenzini L; Ten Kate M; Collij LE; Heeman F; Rikken RM; van der Landen SM; den Hollander ME; Golla SSV; Yaqub M; Windhorst AD; Barkhof F; Scheltens P; de Geus EJC; Visser PJ; van Berckel BNM; den Braber A
Brain; 2023 Sep; 146(9):3735-3746. PubMed ID: 36892415
[TBL] [Abstract][Full Text] [Related]
2. Genetically identical twins show comparable tau PET load and spatial distribution.
Coomans EM; Tomassen J; Ossenkoppele R; Golla SSV; den Hollander M; Collij LE; Weltings E; van der Landen SM; Wolters EE; Windhorst AD; Barkhof F; de Geus EJC; Scheltens P; Visser PJ; van Berckel BNM; den Braber A
Brain; 2022 Oct; 145(10):3571-3581. PubMed ID: 35022652
[TBL] [Abstract][Full Text] [Related]
3. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
4. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.
Tanner JA; Iaccarino L; Edwards L; Asken BM; Gorno-Tempini ML; Kramer JH; Pham J; Perry DC; Possin K; Malpetti M; Mellinger T; Miller BL; Miller Z; Mundada NS; Rosen HJ; Soleimani-Meigooni DN; Strom A; La Joie R; Rabinovici GD
Brain; 2022 Dec; 145(12):4489-4505. PubMed ID: 35762829
[TBL] [Abstract][Full Text] [Related]
5. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
6. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
8. Onset of Preclinical Alzheimer Disease in Monozygotic Twins.
Konijnenberg E; Tomassen J; den Braber A; Ten Kate M; Yaqub M; Mulder SD; Nivard MG; Vanderstichele H; Lammertsma AA; Teunissen CE; van Berckel BNM; Boomsma DI; Scheltens P; Tijms BM; Visser PJ
Ann Neurol; 2021 May; 89(5):987-1000. PubMed ID: 33583080
[TBL] [Abstract][Full Text] [Related]
9. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
[TBL] [Abstract][Full Text] [Related]
10. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
11. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
[TBL] [Abstract][Full Text] [Related]
12. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of sleep duration and physical activity on cognitive performance are influenced by β-amyloid and brain volume but not tau burden among cognitively unimpaired older adults.
Aslanyan V; Ortega N; Fenton L; Harrison TM; Raman R; Mack WJ; Pa J
Neuroimage Clin; 2023; 39():103460. PubMed ID: 37379733
[TBL] [Abstract][Full Text] [Related]
14. Cerebral Microhemorrhage at MRI in Mild Cognitive Impairment and Early Alzheimer Disease: Association with Tau and Amyloid β at PET Imaging.
Rauchmann BS; Ghaseminejad F; Mekala S; Perneczky R;
Radiology; 2020 Jul; 296(1):134-142. PubMed ID: 32368960
[TBL] [Abstract][Full Text] [Related]
15. Identifying longitudinal cognitive resilience from cross-sectional amyloid, tau, and neurodegeneration.
Boyle R; Townsend DL; Klinger HM; Scanlon CE; Yuan Z; Coughlan GT; Seto M; Shirzadi Z; Yau WW; Jutten RJ; Schneider C; Farrell ME; Hanseeuw BJ; Mormino EC; Yang HS; Papp KV; Amariglio RE; Jacobs HIL; Price JC; Chhatwal JP; Schultz AP; Properzi MJ; Rentz DM; Johnson KA; Sperling RA; Hohman TJ; Donohue MC; Buckley RF;
Alzheimers Res Ther; 2024 Jul; 16(1):148. PubMed ID: 38961512
[TBL] [Abstract][Full Text] [Related]
16. Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.
Tideman P; Stomrud E; Leuzy A; Mattsson-Carlgren N; Palmqvist S; Hansson O;
Neurology; 2022 Apr; 98(15):e1525-e1533. PubMed ID: 35022305
[TBL] [Abstract][Full Text] [Related]
17. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
[TBL] [Abstract][Full Text] [Related]
18. Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.
Yang HS; Yau WW; Carlyle BC; Trombetta BA; Zhang C; Shirzadi Z; Schultz AP; Pruzin JJ; Fitzpatrick CD; Kirn DR; Rabin JS; Buckley RF; Hohman TJ; Rentz DM; Tanzi RE; Johnson KA; Sperling RA; Arnold SE; Chhatwal JP
Brain; 2024 Jun; 147(6):2158-2168. PubMed ID: 38315899
[TBL] [Abstract][Full Text] [Related]
19. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
Groot C; Smith R; Stomrud E; Binette AP; Leuzy A; Wuestefeld A; Wisse LEM; Palmqvist S; Mattsson-Carlgren N; Janelidze S; Strandberg O; Ossenkoppele R; Hansson O
Brain; 2023 Apr; 146(4):1580-1591. PubMed ID: 36084009
[TBL] [Abstract][Full Text] [Related]
20. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
